• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·India·Healthcare·ORCHPHARMA.NS
Share

Orchid Pharma Limited Stocks

₹ 1024Last Updated 10.09.2026

Issuer Rating

4/7
Performance

Modest

Risk

Limited

Recommendation

Hold

Market Cap

₹ 514.07M

₹ 1024
Key Takeaways

Risk factor

Limited trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly overvalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Orchid Pharma Limited is a pharmaceutical enterprise primarily focused on the creation, production, and distribution of various pharmaceutical goods within India. Its offerings include active pharmaceutical ingredients (APIs), bulk pharmaceutical materials, finished dosage forms, and nutraceuticals. The company's comprehensive API portfolio features both oral and injectable cephalosporins, alongside specialized products for human and animal health. Additionally, their antibiotic selection encompasses betalactam, macrolide, fluoroquinolone, and imidazole compounds. Beyond its domestic activities, Orchid Pharma Limited also engages in international commerce, exporting its products to approximately 40 countries globally. Established in 1992, the company maintains its corporate headquarters in Chennai, India. It officially adopted its current name, Orchid Pharma Limited, in October 2015, having previously been known as Orchid Chemicals & Pharmaceuticals Limited. Currently, it operates as a subsidiary under Dhanuka Laboratories Limited.

Company Valuation

Greatly overvalued
1/7

From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks. In particular, the stock is overpriced on P/E, 'expensive

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Neutral
4/7

The average target price of ORCHPHARMA.NS is 928 and suggests 3.88% downside potential. Usually, this means a SELL recommendation among investment firms, or a recommendat

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

10.09.2026 21:24

The owner of Vimeo has agreed to acquire Miro, a company with Russian roots, for $1.4 billion

10.09.2026 20:22

Europe's largest airline has warned of the risk of a "significant increase" in prices due to oil prices

10.09.2026 19:47

A Historic Shift: BlackRock Proposes an Alternative to the 60/40 Portfolio

10.09.2026 19:09

"A Bit of Chaos": How Sergey Brin Is Building Gemini in Startup Style in a Kitchen at Google

10.09.2026 18:40

The Nasdaq fell 1% at the start of trading in the U.S. due to a sharp rise in oil prices

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026